Csl Ltd ADR (OP: CSLLY )

100.24 -3.86 (-3.71%)

Streaming Delayed Price Updated: 9:30 AM EDT, Jul 17, 2024 Add to My Watchlist

Price and Volume

Volume	376
Open	104.10
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	104.10
Today's Range	100.24 - 100.24
52wk Range	71.51 - 105.45
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

July 04, 2024

From CSL Behring

Via GlobeNewswire

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

May 20, 2024

From Arcturus Therapeutics

Via Business Wire

Performance

YTD	+3.49%	+3.49%
1 Month	+4.39%	+4.39%
3 Month	+14.13%	+14.13%
6 Month	+7.04%	+7.04%
1 Year	+13.84%	+13.84%

More News

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

April 30, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines

November 02, 2022

Via Benzinga

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks

August 17, 2022

Via Benzinga

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

April 26, 2024

Via Benzinga

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

April 24, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

April 03, 2024

Via MarketBeat

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

February 23, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 05, 2024

From Arcturus Therapeutics

Via Business Wire

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 21, 2023

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

December 13, 2023

Via Benzinga

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 28, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?

September 15, 2023

Via Investor's Business Daily

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

May 18, 2023

From Cara Therapeutics, Inc.

Via GlobeNewswire

OTC Markets Group Welcomes CSL Limited to OTCQX

April 27, 2023

From OTC Markets

Via GlobeNewswire

5 Diverse Medical Stocks To Buy For 2023 And Beyond

April 08, 2023

Via Talk Markets

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories

March 20, 2023

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'

March 20, 2023

Via Benzinga

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

February 28, 2023

From Amarin Corporation plc

Via GlobeNewswire

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

February 21, 2023

Via Benzinga

Why CSL Ltd Stock Could Be Worth a Look

December 03, 2022

Via MarketBeat

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults

November 23, 2022

Via Benzinga

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?

November 02, 2022

Via InvestorPlace

Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder

August 22, 2022

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.